ATRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ATRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
Adhera Therapeutics's adjusted revenue per share for the three months ended in Sep. 2023 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Sep. 2023.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Adhera Therapeutics was 2.40% per year. The lowest was -33.10% per year. And the median was -4.60% per year.
As of today (2024-04-30), Adhera Therapeutics's current stock price is $0.0089. Adhera Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was $0.00. Adhera Therapeutics's Cyclically Adjusted PS Ratio of today is .
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Adhera Therapeutics was 0.10. The lowest was 0.01. And the median was 0.02.
The historical data trend for Adhera Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adhera Therapeutics Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Cyclically Adjusted Revenue per Share | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Adhera Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Adhera Therapeutics's Cyclically Adjusted PS Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Adhera Therapeutics's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Sep. 2023 (Change) | * | Current CPI (Sep. 2023) |
= | 0 | / | 129.8595 | * | 129.8595 | |
= | 0.000 |
Current CPI (Sep. 2023) = 129.8595.
Adhera Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201312 | 11.765 | 98.326 | 15.538 |
201403 | 0.000 | 99.695 | 0.000 |
201406 | 0.000 | 100.560 | 0.000 |
201409 | 0.000 | 100.428 | 0.000 |
201412 | 3.876 | 99.070 | 5.081 |
201503 | 0.000 | 99.621 | 0.000 |
201506 | 2.649 | 100.684 | 3.417 |
201509 | 0.516 | 100.392 | 0.667 |
201512 | 1.290 | 99.792 | 1.679 |
201603 | 0.000 | 100.470 | 0.000 |
201606 | 0.000 | 101.688 | 0.000 |
201609 | 0.000 | 101.861 | 0.000 |
201612 | 0.000 | 101.863 | 0.000 |
201703 | 0.000 | 102.862 | 0.000 |
201706 | 0.000 | 103.349 | 0.000 |
201709 | 0.000 | 104.136 | 0.000 |
201712 | 0.000 | 104.011 | 0.000 |
201803 | 0.000 | 105.290 | 0.000 |
201806 | 0.000 | 106.317 | 0.000 |
201809 | 0.240 | 106.507 | 0.293 |
201812 | -0.110 | 105.998 | -0.135 |
201903 | 0.006 | 107.251 | 0.007 |
201906 | 0.122 | 108.070 | 0.147 |
201909 | 0.094 | 108.329 | 0.113 |
201912 | 0.243 | 108.420 | 0.291 |
202003 | 0.000 | 108.902 | 0.000 |
202006 | 0.000 | 108.767 | 0.000 |
202009 | 0.000 | 109.815 | 0.000 |
202012 | 0.000 | 109.897 | 0.000 |
202103 | 0.000 | 111.754 | 0.000 |
202106 | 0.000 | 114.631 | 0.000 |
202109 | 0.000 | 115.734 | 0.000 |
202112 | 0.000 | 117.630 | 0.000 |
202203 | 0.000 | 121.301 | 0.000 |
202206 | 0.000 | 125.017 | 0.000 |
202209 | 0.000 | 125.227 | 0.000 |
202212 | 0.000 | 125.222 | 0.000 |
202303 | 0.000 | 127.348 | 0.000 |
202306 | 0.000 | 128.729 | 0.000 |
202309 | 0.000 | 129.860 | 0.000 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.
For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Adhera Therapeutics was 0.10. The lowest was 0.01. And the median was 0.02.
Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.
Thank you for viewing the detailed overview of Adhera Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Zahed Subhan | director | 8000 INNOVATION PARKWAY, BATON ROUGE LA 70820 |
Trond Kydd Waerness | director | 8000 INNOVATION PARKWAY, BAON ROUGE LA 70820 |
Rice Charles L Jr | director | C/O ENTERGY CORPORATION LEGAL DEPT., 639 LOYOLA AVE., 26TH FLOOR, NEW ORLEANS LA 70113 |
Andrew Albert Kucharchuk | director, officer: Chief Executive Officer | 549 MILGATE PLACE, BATON ROUGE LA 70810 |
Rhonda L. Stanley | officer: SVP Finance & Accounting | 5001 SOUTH MIAMA BOULEVARD, SUITE 300, DURHAM NC 27703 |
Nancy R. Phelan | director | 812 MAPLEWOOD ROAD, WAYNE PA 19087 |
Robert Eric Teague | officer: Chief Financial Officer | C/O MARINA BIOTECH, INC., 4721 EMPEROR BOULEVARD, SUITE 350, DURHAM NC 27703 |
Uli Hacksell | director | 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121 |
Robert Jr. Moscato | officer: CEO | 400 PRATT STREET, SUITE 606, BALTIMORE MD 21202 |
Timothy Boris | director | 805 AEROVISTA PLACE, SUITE 205, SAN LUIS OBISPO CA 93401 |
Isaac Blech | director | C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116 |
Peter D. Weinstein | officer: Chief Legal Officer | C.O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748 |
Amit B. Shah | officer: Chief Financial Officer | 10 AGUILA, ALISO VIEJO CA 92656 |
Erik C. Emerson | officer: Chief Commercial Officer | 2300 WEST SAHARA AVENUE, SUITE 800 - #4012, LAS VEGAS NV 89102 |
Mihir Munsif | officer: Chief Operating Officer | 21102 BRIARWOOD LANE, TRABUCO CANYON CA 92679 |
From GuruFocus
By gurufocus 10qk • 11-15-2010
By gurufocus • 05-15-2009
By [email protected] [email protected] • 09-06-2019
By GuruFocusNews GuruFocusNews • 06-28-2022
By gurufocus 10qk • 05-17-2010
By GlobeNewswire GlobeNewswire • 11-21-2018
By Marketwired Marketwired • 09-27-2019
By ACCESSWIRE AccessWire • 04-12-2019
By ACCESSWIRE AccessWire • 04-12-2019
By Marketwired Marketwired • 06-20-2018